Effectiveness of Fuzheng Qudu Decoction Combined with Antiviral Regimen in the Treatment of Chronic HBV Infection-Related Cirrhosis and the Effect on HBV-DNA Load
SUN Min, LI Mi, DUAN Mingling
Deyang People' s Hospital, Sichuan Deyang 618000, China
Abstract：Objective: To analyze the Effectiveness of Fuzheng Qudu decoction combined with antiviral regimen in the treatment of chronic hepatitis B (HBV) infection-related liver cirrhosis and its effect on hepatitis B virus deoxyribonucleic acid (HBV-DNA) load. Methods: A total of 218 patients with chronic HBV infection-related liver cirrhosis treated in the hospital between October 2019 and October 2021 were selected, and they were divided into combined group (given Fuzheng Qudu decoction combined with entecavir antiviral therapy, n=109) and control group (treated with entecavir antiviral therapy, n=109) according to the simple random grouping method. The clinical efficacy and scores of TCM syndromes, HBV-DNA load and positive rate and negative conversion rate of hepatitis B surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg) of the two groups were compared after 12 weeks of treatment. The levels of liver function indicators [alanine aminotransferase (ALT), serum albumin (ALB), total bilirubin (TBIL), aspartate aminotransferase (AST)] before and after treatment and levels of serum inflammatory factors [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8)] were compared between the two groups. Results: The decreases of scores of TCM syndromes before and after treatment were higher in combined group compared to control group (P<0.05), and the clinical effective rate of 92.66% was higher than 83.49% in control group (P<0.05). The decrease of HBV-DNA load before and after treatment in combined group was higher compared with that in control group (P<0.05), and the negative conversion rates of HBV-DNA, HBsAg and HBeAg were higher compared with those in control group (P<0.05). The levels of ALT, TBIL and AST and inflammatory indicators TNF-α, IL-6 and IL-8 in combined group after treatment were lower than those in control group while the level of ALB was higher than that in control group (P<0.05), and the decreases of the above indicators in combined group before and after treatment were higher than those in control group (P<0.05). Conclusion: Fuzheng Qudu decoction combined with antiviral therapy has a significant clinical efficacy in the treatment of chronic HBV-related liver cirrhosis, and it can inhibit the body’s inflammatory response, enhance the body’s immune response, inhibit the HBV-DNA replication, reduce the viral load and improve the liver function.
孙敏, 李觅, 段明玲. 扶正祛毒方联合抗病毒方案治疗慢性HBV感染相关肝硬化的效果及对HBV-DNA载量的影响[J]. 河北医学, 2022, 28(8): 1387-1392.
SUN Min, LI Mi, DUAN Mingling. Effectiveness of Fuzheng Qudu Decoction Combined with Antiviral Regimen in the Treatment of Chronic HBV Infection-Related Cirrhosis and the Effect on HBV-DNA Load. HeBei Med, 2022, 28(8): 1387-1392.
[1] 段红岩.微生态制剂联合抗病毒治疗对乙肝肝硬化患者免疫功能及肝纤维化指标的影响[J].河北医学,2019,25(11):1861-1865. [2] Nishikawa K,Osawa Y,Kimura K.Wnt/β-catenin signaling as a potential target for the treatment of liver cirrhosis using antifibrotic Drugs[J].Int Mol Sci,2018,19(10):3103. [3] 李璐,胡冬青,孙建光,等.基于"祛邪为先"理念探讨中西医结合治疗乙型肝炎肝硬化思路和方法[J].山东中医杂志,2019,38(7):624-628,637. [4] 高奎亮,李薇,徐广鑫,等.脾胃升降相因对药应用经验[J].中医学报,2019,34(7):1397-1400. [5] 中华医学会肝病学分会.肝硬化诊治指南[J].中华肝脏病杂志,2019,27(11):846-865. [6] 冯明洋,丁叶舟,赵青青,等.肝衰竭患者中医证型与西医肝衰竭分期之间的关系观察[J].诊断学理论与实践,2021,20(4):391-395. [7] 郑筱萸.中药新药临床研究指导原则[M].中国医药科技出版社,2002. [8] Mak LY,Cloherty G,Wong DK,et al.HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy[J].Hepatology,2021,73(6):2167-2179. [9] 李偲,郑佳连,王岩,等.基于中医传承辅助平台的卢秉久辨治乙型肝炎肝硬化用药分析[J].辽宁中医杂志,2020,47(4):47-51. [10] 张云富,孟静岩.《素问》七篇大论三阴三阳六气内涵及致病特点[J].云南中医学院学报,2021,44(1):47-50. [11] Feng S,Ding H,Liu L,et al.Astragalus polysaccharide enhances the immune function of RAW264.7 macrophages via the NF-κB p65/MAPK signaling pathway[J].Exp Ther Med,2021,21(1):20.
2022, Vol. 28 
冀公网安备13080202000677号